Harnett, Mark D.

Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial

Berry-Kravis, E. M., Harnett, M. D., Reines, S. A., Reese, M. A., Ethridge, L. E., Outterson, A. H., Michalak, C., Furman, J., & Gurney, M. E. (2021) · Nature Medicine

Genetics and Neurodevelopmental DisordersPhosphodiesterase function and regulation

Cited by 131

Misuse of Tramadol in the United States: An Analysis of the National Survey of Drug Use and Health 2002-2017

Reines, S. A., Goldmann, B., Harnett, M., & Lu, L. (2020) · Substance Abuse: Research and Treatment

Opioid Use Disorder TreatmentSubstance Abuse Treatment and Outcomes

Cited by 41

Intepirdine as adjunctive therapy to donepezil for mild‐to‐moderate Alzheimer's disease: A randomized, placebo‐controlled, phase 3 clinical trial (MINDSET)

Lang, F. M., Mo, Y., Sabbagh, M., Solomon, P., Boada, M., Jones, R. W., Frisoni, G. B., Grimmer, T., Dubois, B., Harnett, M., et al. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 34

A randomized phase 1 evaluation of deupirfenidone, a novel deuterium-containing drug candidate for interstitial lung disease and other inflammatory and fibrotic diseases

Chen, M. C., Korth, C. C., Harnett, M. D., Elenko, E., & Lickliter, J. D. (2022) · Clinical Pharmacology in Drug Development

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPharmacogenetics and Drug Metabolism

Cited by 18